journal
MENU ▼
Read by QxMD icon Read
search

Lung Cancer: Journal of the International Association for the Study of Lung Cancer

journal
https://www.readbyqxmd.com/read/30342857/molecular-determinants-of-acquired-resistance-to-braf-inhibition-in-human-lung-cancer
#1
LETTER
Carlo Lucchesi, Benjamin Drogat, David Santamaria, Sophie Cousin, Antoine Italiano
No abstract text is available yet for this article.
October 12, 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30287081/corrigendum-to-routine-preoperative-brain-ct-in-resectable-non-small-cell-lung-cancer-ten-years-experience-from-a-tertiary-uk-thoracic-center-lung-cancer-122-august-2018-195-199
#2
Tomasz Matys, Rosalyn Drury, Sarojini David, Doris M Rassl, Wendi Qian, Robert C Rintoul, Nicholas J Screaton
No abstract text is available yet for this article.
October 1, 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30292401/comment-on-pneumonitis-in-advanced-non-small-cell-lung-cancer-patients-treated-with-egfr-tyrosine-kinase-inhibitor-meta-analysis-of-153-cohorts-with-15-713-patients-meta-analysis-of-incidence-and-risk-factors-of-egfr-tki-pneumonitis-in-nsclc
#3
LETTER
Ran Xu, Jing Zhu
No abstract text is available yet for this article.
September 24, 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30217601/comment-on-erlotinib-in-combination-with-bevacizumab-has-potential-benefit-in-non-small-cell-lung-cancer-a-systematic-review-and-meta-analysis-of-randomized-clinical-trials
#4
LETTER
Ran Xu, Jing Zhu
No abstract text is available yet for this article.
September 7, 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30268487/highlights-of-the-14th-international-mesothelioma-interest-group-meeting-pathologic-separation-of-benign-from-malignant-mesothelial-proliferations-and-histologic-molecular-analysis-of-malignant-mesothelioma-subtypes
#5
Andrew Churg, Kazuki Nabeshima, Greta Ali, Rossella Bruno, Lynnette Fernandez-Cuesta, Francoise Galateau-Salle
OBJECTIVES: The separation of benign from malignant mesothelial proliferations and exact subclassification of mesothelioma subtypes is crucial to determining patient care and prognosis but morphologically can be very difficult. METHODS: This session of the 2018 IMIG meeting addressed these problems. RESULTS: A new immunohistochemical marker, methylthioadenosine phosphorylase, was shown to correlate well with CDKN2A FISH and is cheaper and faster to run...
October 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30268486/automated-chromogenic-multiplexed-immunohistochemistry-assay-for-diagnosis-and-predictive-biomarker-testing-in-non-small-cell-lung-cancer
#6
Marius Ilie, Mélanie Beaulande, Marame Hamila, Gilles Erb, Véronique Hofman, Paul Hofman
OBJECTIVES: The current challenge in the management of non-small cell lung cancer (NSCLC) in pathology laboratories is to combine immunohistochemistry (IHC) and molecular approaches on increasingly smaller biopsies and the need to reserve a fair amount of tumor material for molecular analyses with increasingly larger panels. The latest lung cancer classification, especially in the setting of poorly differentiated tumors, requires an IHC workup to allow for accurate diagnosis and also to preserve as much tissue as possible for molecular testing...
October 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30268485/carving-out-another-slice-of-the-pie-exceptional-response-to-single-agent-imatinib-in-an-asian-female-never-smoker-with-advanced-nsclc-with-a-de-novo-pdgfr-%C3%AE-n848-k-mutation
#7
Samuel J Klempner, Kyle Gowen, Thomas K Lee, Viola W Zhu, Alexa B Schrock, Vincent A Miller, Siraj M Ali, Sai-Hong Ignatius Ou
Non-small cell lung cancer (NSCLC) has emerged as a paradigm for clinical application of precision medicine as optimal therapy is commonly chosen based on genomic biomarkers identified in a patient's tumor sample. Recurrent driver alterations are well described, however, a need to continually identify rare variants remains clinically relevant. We identified an incident case of advanced NSCLC with a PDGFR-α N848 K activation loop mutation with no other concurrent oncogenic drivers. Amino acid sequence alignment confirmed homology to the imatinib-sensitive KIT N822 K activation loop mutation observed in GIST...
October 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30268484/invasive-nodal-evaluation-prior-to-stereotactic-ablative-radiation-for-non-small-cell-lung-cancer
#8
Jeremy P Harris, Chika Nwachukwu, Yushen Qian, Erqi Pollom, Billy W Loo, Millie Das, Maximilian Diehn
INTRODUCTION: Invasive nodal evaluation (INE) is used to improve staging for early stage non-small cell lung cancer (NSCLC), including when stereotactic ablative radiation (SABR) is used. Consensus guidelines from the NCCN recommend performing INE for patients with T2N0 tumors and considering INE for those with T1N0 tumors. We reasoned that if INE results in significant stage migration in the form of substantially fewer patients with occult nodal involvement, then patients treated with SABR who do not undergo INE should have worse overall survival (OS)...
October 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30268483/egfr-and-her3-signaling-blockade-in-invasive-mucinous-lung-adenocarcinoma-harboring-an-nrg1-fusion
#9
Hye Sook Kim, Ji-Youn Han, Dong Hoon Shin, Kun Young Lim, Geon Kook Lee, Jin Young Kim, Wolfgang Jacob, M Ceppi, Martin Weisser, I James
Rearrangements of NRG1 have been identified in invasive mucinous adenocarcinoma of the lung (IMA), formerly referred to as mucinous bronchioloalveolar carcinoma. NRG1 ligand signals through induction of HER2-HER3 heterodimers, thus leading to PI3K-AKT pathway activation. Therefore, targeting HER2, HER3 and the downstream pathway may be a hypothesis-driven strategy for IMA with NRG1 fusion. Herein we reported two patients who benefited from lumretuzumab, a monoclonal anti-HER3 antibody, in combination of erlotinib during a clinical trial (NCT01482377)...
October 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30268482/phase-ii-trial-of-gefitinib-plus-pemetrexed-after-relapse-using-first-line-gefitinib-in-patients-with-non-small-cell-lung-cancer-harboring-egfr-gene-mutations
#10
Ken Uchibori, Miyako Satouchi, Naoko Sueoka-Aragane, Yoshiko Urata, Akemi Sato, Fumio Imamura, Takako Inoue, Motoko Tachihara, Kazuyuki Kobayashi, Nobuyuki Katakami, Chiyuki Kokan, Tomonori Hirashima, Kentaro Iwanaga, Masahide Mori, Keisuke Aoe, Satoshi Morita, Shunichi Negoro
OBJECTIVES: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (i.e., EGFR-TKIs) improve the survival of lung cancer patients harboring EGFR mutations. Despite the initial efficacy of EGFR-TKIs, the disease progression caused by acquired resistance to these inhibitors is inevitable. T790M mutations represent a major resistance mechanism to EGFR-TKIs but can be overcome using osimertinib. The IMPRESS trial revealed that the continuation of EGFR-TKI beyond progressive disease (PD) concurrent with platinum-doublet chemotherapy was not beneficial...
October 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30268481/applicability-of-a-prognostic-ct-based-radiomic-signature-model-trained-on-stage-i-iii-non-small-cell-lung-cancer-in-stage-iv-non-small-cell-lung-cancer
#11
Evelyn E C de Jong, Wouter van Elmpt, Stefania Rizzo, Anna Colarieti, Gianluca Spitaleri, Ralph T H Leijenaar, Arthur Jochems, Lizza E L Hendriks, Esther G C Troost, Bart Reymen, Anne-Marie C Dingemans, Philippe Lambin
OBJECTIVES: Recently it has been shown that radiomic features of computed tomography (CT) have prognostic information in stage I-III non-small cell lung cancer (NSCLC) patients. We aim to validate this prognostic radiomic signature in stage IV adenocarcinoma patients undergoing chemotherapy. MATERIALS AND METHODS: Two datasets of chemo-naive stage IV adenocarcinoma patients were investigated, dataset 1: 285 patients with CTs performed in a single center; dataset 2: 223 patients included in a multicenter clinical trial...
October 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30268480/kras-mutant-non-small-cell-lung-cancer-from-biology-to-therapy
#12
REVIEW
Irene Ferrer, Jon Zugazagoitia, Stephan Herbertz, William John, Luis Paz-Ares, Gerald Schmid-Bindert
In patients with non-small cell lung cancer (NSCLC), the most frequent oncogene driver mutation in Western countries is Kirsten rat sarcoma viral oncogene homolog (KRAS), and KRAS-mutant NSCLC is associated with smoking. There are various sources of biological heterogeneity of KRAS-mutant NSCLC, including different genotypes that may be associated with specific clinical outcomes, the presence of other co-mutations that exhibit different biological features and drug sensitivity patterns, and mutant allelic content...
October 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30268479/exosomal-rna-profiling-of-pleural-effusions-identifies-adenocarcinoma-patients-through-elevated-mir-200-and-lcn2-expression
#13
Per Hydbring, Luigi De Petris, Yanming Zhang, Eva Brandén, Hirsh Koyi, Metka Novak, Lena Kanter, Petra Hååg, James Hurley, Vasisht Tadigotla, Baoli Zhu, Johan Skog, Kristina Viktorsson, Simon Ekman, Rolf Lewensohn
HYPOTHESIS: The inherent challenges associated with tissue biopsies from lung have spurred an interest in the use of liquid biopsies. Pleural effusions are one source of liquid biopsy. Recently, extracellular vesicles of endocytic origin, exosomes, have attracted interest as liquid biopsy of tumors as they are thought to be a mirror of their tumor of origin. Here, we aimed to analyze if RNA profiling of exosomes isolated from pleural effusions could differentiate patients with lung adenocarcinoma from patients with benign inflammatory processes...
October 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30268478/smoking-alcohol-and-nutritional-status-in-relation-to-one-year-mortality-in-danish-stage-i-lung-cancer-patients
#14
Niels Lyhne Christensen, Anders Løkke, Susanne Oksbjerg Dalton, Jane Christensen, Torben Riis Rasmussen
INTRODUCTION: In addition to the highest incidence rate of lung cancer among the Nordic countries, Denmark has the highest mortality rate. Moreover, rates of tobacco and alcohol consumption are among the highest in these countries. METHOD: In a population-based matched case/control study, we aimed to assess the association between one-year all-cause mortality and a number of smoking-related parameters, high-risk alcohol intake, and nutritional status in clinical stage I lung cancer patients...
October 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30268477/elongation-factor-2-kinase-eef-2k-expression-is-associated-with-poor-patient-survival-and-promotes-proliferation-invasion-and-tumor-growth-of-lung-cancer
#15
Haci Ahmet Bircan, Nilgun Gurbuz, Apar Pataer, Ayse Caner, Nermin Kahraman, Emine Bayraktar, Recep Bayraktar, Mumin Alper Erdogan, Nashwa Kabil, Bulent Ozpolat
OBJECTIVES: Lung cancer is the leading cause of cancer related deaths in worldwide. Despite recent advances in treatment options, patient survival has not improved substantially due to lack of commonly expressed molecular targets and effective targeted therapeutics. Thus, better understanding of the biology of lung cancer and identification of novel therapeutic targets are urgently needed for development of highly effective molecularly targeted therapies. MATERIALS AND METHODS: Viability, proliferation and metastatic ability of lung cancer cells were evaluated using methylthiazoltetrazolium (MTT), colony formation and matrigel invasion assays, respectively...
October 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30268476/continuation-of-gefitinib-beyond-progression-in-patients-with-egfr-mutation-positive-non-small-cell-lung-cancer-a-phase-ii-single-arm-trial
#16
Sung Won Lim, Sehhoon Park, Youjin Kim, Jang Ho Cho, Song Ee Park, Hansang Lee, Hee Kyung Kim, Sung Min Kim, Jong Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
OBJECTIVES: Several studies have demonstrated the promise of continuation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) beyond progression in patients with EGFR-mutant non-small-cell lung cancer (NSCLC). The aim of the present study is to clarify the efficacy of continuation of gefitinib in patients with NSCLC beyond progression. MATERIALS AND METHODS: A total of 50 patients with EGFR-mutant NSCLC who progressed based on Response Evaluation Criteria in Solid Tumors (RECIST) 1...
October 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30268475/synchronous-multiple-non-small-cell-lung-cancers-in-an-allograft-lung-recipient
#17
Jean-Louis Pujol, Sandy Jean-Baptiste, Sébastien Bommart, Benoît Roch
We described a case report of synchronous non-small cell lung cancers arising in lung transplants after allograft. Immunosuppressive therapy of the recipient induced an accelerated growth rate of primary tumour and metastases as was been observed in orthotopic liver allograft for hepatocellular carcinoma.
October 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30268474/dose-escalation-and-associated-predictors-of-survival-with-consolidative-thoracic-radiotherapy-in-extensive-stage-small-cell-lung-cancer-sclc-a-national-cancer-database-ncdb-propensity-matched-analysis
#18
Shaakir Hasan, Paul Renz, Andrew Turrisi, Athanasios Colonias, Gene Finley, Rodney E Wegner
PURPOSE: Randomized studies have demonstrated a survival benefit for consolidative thoracic radiotherapy (TRT) in extensive stage (ES) small cell lung cancer (SCLC), however the radiation dose and optimal selection criteria are often debated. METHODS: We analyzed 3280 stage IV SCLC treated with double-agent chemotherapy and TRT within the National Cancer Data Base (NCDB) and evaluated the differences in selection patterns and survival outcomes for patients who received at least 45 Gy of TRT and those who received <45 Gy...
October 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30268473/probable-hereditary-familial-overlap-syndrome-with-multiple-synchronous-lung-tumors
#19
Andrés F Cardona, Zyanya Lucia Zatarain-Barrón, Cladelis Rubio, Stella Martínez, Alejandro Ruiz-Patiño, Luisa Ricaurte, Adriana Serna, Rodolfo Barrios, Juan Carlos Garzón, Constanza Navarrete, Alberto Balaguera, Luis Corrales, Leonardo Rojas, Oscar Arrieta
Here we report a case of a young, never-smoker Hispanic woman with a hereditary familial overlap syndrome (Li-Fraumeni plus CDH1). The patient developed multiple synchronous primary lung adenocarcinomas related to Intra-Alveolar Tumor Spread (STAS) several years after the diagnosis of a locally advanced lower limb osteosarcoma. Comprehensive genomic profiling by next generation sequencing (NGS) was performed on 90 cancer-related genes over each lung lesion (including two nodules of acinar adenocarcinoma, one lepidic spread tumor and in the STAS area)...
October 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30268472/bcl-2-expression-in-circulating-tumor-cells-ctcs-of-patients-with-small-cell-lung-cancer-sclc-receiving-front-line-treatment
#20
Ippokratis Messaritakis, Michail Nikolaou, Eleni Politaki, Fillipos Koinis, Eleni Lagoudaki, Anastasios Koutsopoulos, Nefeli Georgoulia, Vassilis Georgoulias, Athanasios Kotsakis
INTRODUCTION: To investigate the presence of Bcl-2+ CTCs in chemotherapy-naïve SCLC patients and their clinical relevance during front-line treatment. METHODS: Peripheral blood was obtained from 66 consecutive-patients before chemotherapy administration, after one-cycle and at relapse. CTCs were detected by CellSearch and immunofluorescence using anti-Bcl-2, anti-M30, anti-cytokeratins(CK), anti-CD45 and anti-vimentin(Vim) antibodies. RESULTS: Before treatment, CTCs were detected in 62...
October 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
journal
journal
29732
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"